Amarantus Bioscience Holdings Inc (AMBS)

Currency in USD
0.0003
0.0000(0.00%)
Closed·
AMBS Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week Low
Fair Value
Day's Range
0.00010.0003
52 wk Range
0.00010.0401
Key Statistics
Prev. Close
-
Open
0.0001
Day's Range
0.0001-0.0003
52 wk Range
0.0001-0.0401
Volume
-
Average Volume (3m)
7.9K
1-Year Change
200%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMBS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Amarantus Bioscience Holdings Inc Company Profile

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Compare AMBS to Peers and Sector

Metrics to compare
AMBS
Peers
Sector
Relationship
P/E Ratio
0.0x−5.4x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x2.3x2.6x
Price / LTM Sales
0.0x9.4x3.2x
Upside (Analyst Target)
0.0%161.6%41.7%
Fair Value Upside
Unlock8.8%6.1%Unlock

Earnings

Latest Release
Nov 25, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AMBS Income Statement

FAQ

What Stock Exchange Does Amarantus Bioscience Holdings Trade On?

Amarantus Bioscience Holdings is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Amarantus Bioscience Holdings?

The stock symbol for Amarantus Bioscience Holdings is "AMBS."

What Is the Amarantus Bioscience Holdings Market Cap?

As of today, Amarantus Bioscience Holdings market cap is 630.00.

What Is Amarantus Bioscience Holdings's Earnings Per Share (TTM)?

The Amarantus Bioscience Holdings EPS (TTM) is -0.03.

From a Technical Analysis Perspective, Is AMBS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Amarantus Bioscience Holdings Stock Split?

Amarantus Bioscience Holdings has split 2 times.

How Many Employees Does Amarantus Bioscience Holdings Have?

Amarantus Bioscience Holdings has 12 employees.

What is the current trading status of Amarantus Bioscience Holdings (AMBS)?

As of 26 Jul 2025, Amarantus Bioscience Holdings (AMBS) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.04.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.